Participant population
Out of the 783 participants who were screened, this analysis included 500 eligible participants intended for vaccination at six locations in the Russian Federation between 11 September 2020 and 11 November 2020. Of these, 374 participants were randomised to the Ad5-nCoV group and 126 to the Placebo group (